Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.61 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29569996 | 0.91 | OPRM1 (0.75) | OPRM1OPRD1F2NTSR1NTSR2 | |
| SCHEMBL31114471 | 0.90 | OPRM1 (0.63) | OPRM1OPRD1NTSR1NTSR2SORT1 | |
| SCHEMBL29630683 | 0.90 | OPRM1 (0.71) | OPRM1OPRD1F2NTSR1NTSR2 | |
| SCHEMBL30273400 | 0.88 | OPRM1 (0.64) | OPRM1OPRD1F2NTSR1NTSR2 | |
| SCHEMBL29753383 | 0.88 | OPRM1 (0.57) | OPRM1OPRD1NTSR1NTSR2SORT1 | |
| SCHEMBL31370870 | 0.88 | OPRM1 (0.63) | OPRM1OPRD1NTSR1NTSR2SORT1 | |
| SCHEMBL31679387 | 0.87 | OPRM1 (0.66) | OPRM1OPRD1F2SLC6A2 | |
| SCHEMBL31114385 | 0.87 | OPRM1 (0.57) | OPRM1OPRD1NTSR1NTSR2SORT1 | |
| SCHEMBL30232040 | 0.87 | OPRM1 (0.65) | OPRM1OPRD1NTSR1NTSR2SORT1 | |
| SCHEMBL31114354 | 0.87 | OPRM1 (0.62) | OPRM1OPRD1F2NTSR1NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241377-A1 | RECEPTOR-TARGETING PEPTIDE-DRUG CONJUGATES | Molgenie GmbH (DE) | 2022-08-04 | — | — | US | claimed |
| EP-4003403-A1 | RECEPTOR-TARGETING PEPTIDE-DRUG CONJUGATES | Molgenie GmbH (DE) | 2022-06-01 | — | — | EP | claimed |
| CN-114450299-A | Receptor-targeting peptide-drug conjugates | 莫尔吉尼有限责任公司 | 2022-05-06 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241377-A1 | RECEPTOR-TARGETING PEPTIDE-DRUG CONJUGATES | NPY1R, NPY2R, NPY5R | OPRM1 300/4885OPRD1 601/4885F2 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.